In a phase I basket study enrolling 166 patients with PIK3CA mutant solid tumours, taselisib showed limited activity (9% RR), with a partial response in a subset of pancreatic cancer patients (sarcomatoid and pseudopapillary). Here, PIK3CA is linked to pancreatic neoplasm.